Florence Healthcare’s Senior Implementation Manager Amanda Korey presents a roadmap that not only fosters collaboration between sites, sponsors and CROs, but also results in robust user adoption across all stakeholder groups.
If you are not happy with the results below please do another search
50 search results for:
Four drugmakers, including Johnson & Johnson and Teva Pharmaceutical Industries Ltd., will go to trial on April 19 over claims they helped fuel an opioid crisis that has resulted in nearly 500,000 overdose deaths in the United States.
U.S. Food and Drug Administration Approves Opdivo®(nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma — Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival versus chemotherapy alone in a trial of this patient population1 April 16, 2021 […]
A U.S. panel will meet again next week to discuss whether the pause on the use of Johnson & Johnson’s Covid-19 vaccine should continue, after delaying a vote on the matter earlier this week.
A new study by researchers at the University College London (UCL) published in Lancet Infectious Diseases finds that although the U.K. variant of SARS-CoV-2 known as B.1.1.7 is more transmissible than the wild-type, original Wuhan strain, it is likely not more deadly.
The Biden administration on April 16 said it will invest $1.7 billion to help states and the U.S. Centers for Disease Control and Prevention fight Covid-19 variants that are rapidly spreading across the United States.
In an effort to boost drug discovery for the “toughest drug discovery problems” through the use of machine learning, precision medicines company Relay Therapeutics is acquiring Waltham, Mass.-based ZebiAI with an $85 million upfront payment.
Eli Lilly requested cancellation of the U.S. authorization granted to the company’s Covid-19 antibody bamlanivimab, which will now be used in combination with another to achieve greater efficacy against emerging virus variants.
The number of new Covid-19 cases per week nearly doubled globally over the past two months, approaching the highest rate seen so far during the pandemic, the head of the World Health Organization (WHO) said on April 16.
Shares of Inovio climbed in trading after the company announced its DNA vaccine candidate for Covid-19 induced a robust T-cell response against multiple variants of the SARS-CoV-2 virus.